Browsing Tag
Daiichi Sankyo
33 posts
AVCT entry at 86p is a bet on AVA6103: What Avacta Group investors should know
Avacta Group sets up a binary AVA6103 readout for late H2 2026. Here is what AVCT retail investors need to weigh before the data lands and runway runs.
May 20, 2026
AstraZeneca, Daiichi Sankyo secure FDA approval for Enhertu in two early breast cancer indications
Enhertu is moving from late-stage control to early-stage cure. AstraZeneca and Daiichi Sankyo now face the bigger test: adoption.
May 16, 2026
Avacta Group (AIM: AVCT) preCISION data signals tumor selectivity index emerging as the new ADC battleground
Avacta is not just challenging Enhertu. It is rewriting the metric the entire ADC industry will be diligenced on. Tumor selectivity is the new battleground.
May 10, 2026
Avacta Group (AIM: AVCT) delivers preCISION payload data that challenges Enhertu and Datroway tumor selectivity at Science Day 2026
Avacta is no longer pitching a platform. It is benchmarking preCISION directly against Enhertu and Datroway, and the tumor selectivity numbers matter.
May 6, 2026
Aditxt eyes Pearsanta IPO and oncology pivot as ADTX (NASDAQ) tests retail patience
Aditxt regained Nasdaq compliance, then filed to issue 148 million shares. ADTX retail investors are watching Pearsanta's IPO and a bitXbio crypto pivot.
May 2, 2026
AVCT stock near 52-week high as Avacta Group pre|CISION data challenges Enhertu benchmark at AACR 2026
Avacta Group (AIM: AVCT) AACR 2026 data show AVA6103 outperforms Enhertu on tumor selectivity while AVA6207 delivers first in vivo dual payload results. Read our analysis.
April 22, 2026
AstraZeneca, Daiichi Sankyo score tenth BTD for Enhertu in early HER2 disease
AstraZeneca and Daiichi Sankyo’s Enhertu earns FDA breakthrough tag in early breast cancer. Find out what this means for HER2 treatment strategy in 2025.
January 2, 2026
AstraZeneca and Daiichi Sankyo win FDA approval for Enhertu combo as new standard in HER2 mBC
Enhertu plus pertuzumab gets FDA approval for first-line HER2-positive mBC, setting a new standard in metastatic breast cancer care. Read what changes now.
December 17, 2025
General Proximity inks Daiichi Sankyo deal to push precision small molecules into oncology
General Proximity partners with Daiichi Sankyo to develop proximity-based cancer drugs using OmniTAC. Discover how this biotech is redefining drug discovery.
November 12, 2025
Half of platinum-resistant ovarian cancer patients respond to Raludotatug deruxtecan in REJOICE-Ovarian01 trial
Find out how Raludotatug deruxtecan achieved a 50 % response rate in platinum-resistant ovarian cancer and what it means for future ADC therapies.
October 20, 2025